Melbourne is home to two outstanding universities, Monash University and the University of Melbourne. Together they are ranked globally among the top Universities for Life Sciences & Medicine. Joining these two powerhouses to support the collaborative joint venture BioCurate, is the Victorian State Government.
The combined research strengths of Monash University and the University of Melbourne are world class, placing them in the top 5 globally in pharmacology, metabolism, and immunology, and in the top 10 in paediatrics, neurosciences and cardiology – thereby covering some of the most debilitating, costly diseases in the modern world.
The Universities collectively invest approximately AUD1B per annum in medical research funding and in 2016 attracted nearly half of the Australian national grant funding pool. Both Universities are members of the ‘Group of Eight’, an alliance of leading Australian universities recognised for their excellence in teaching as well as research. Between them, the Universities employ approximately 4,000 FTE staff in the biomedical sciences and provide major research infrastructure, healthcare and clinical research capabilities.
As individual institutions, Monash University and the University of Melbourne have differing, yet potentially highly complementary areas of expertise required for the early drug development process. This provides a compelling opportunity for BioCurate to be the catalyst to identify and leverage this combined expertise and build a strong pipeline of new drug targets with the potential to make a significant impact both medically and commercially.
Monash University is Australia’s largest university. In the 60 years since foundation, we’ve built a reputation for world-leading, high-impact research, quality teaching, and inspiring innovation and learning culture.
Our size and scale – along with our growing global network – enable us to dial-up our education and research on an international scale. With four campuses in Australia, and a presence in Malaysia, China, India, Indonesia and Italy, our people are part of a thriving connected community.
At Monash, we’re redefining what it means to be a university. We transcend disciplines and boundaries, going beyond education and research to see the connections and intersections that others don’t. Our role is as a catalyst for resolving the complex challenges facing our world now and for every generation to come. And we know that it’s through deep, robust, sustainable partnerships with industry, government and the community that we’re going to do it.
The University of Melbourne is a global leader in higher education. Across our campuses we convene brilliant minds from different disciplines and sectors to come together to address important questions and tackle grand challenges. In a disrupted world, that capacity has never been more important.
In the spirit of discovery, the University convenes experts from around the world to tackle complex problems in innovative ways with investigator-led, interdisciplinary collaboration central to our purpose as a comprehensive research organisation. The University works with industry partners and specialist research institutes to address the major challenges that exist in the world.
The University is embedded within world- leading clusters of expertise, including the Melbourne Biomedical Precinct, Melbourne Innovation District through Melbourne Connect, Southbank Arts Precinct, and the heavy engineering and design precinct to be located at Fishermans Bend. The University plays a leading role within these precincts to amplify the benefits of research.
Victoria is one of the world’s leading life science hubs, including the medical technology, biotechnology and pharmaceutical industry segments, which is supported by 16 major medical research institutes, 11 teaching hospitals and 9 universities.
Victoria is a leading generator of new ideas contributing to drug discovery and development, and to the global pipeline of new drugs. Built on world- class research, a vibrant biotech sector, key R&D infrastructure and manufacturing expertise, Victoria is currently home to 41 ASX-listed pharmaceutical and biotechnology companies, with a combined market capitalisation of over $135 billion. More than 22 pharmaceutical manufacturers are based in Melbourne producing a variety of products for international markets using advanced manufacturing technologies. In 2019, Victoria’s pharmaceutical products exports accounted for $3.09 billion, an increase of 242% since 2015. Pharmaceuticals are now Victoria’s highest-value manufactured export product.
This pre-eminent position has been made possible by the consistent and long-term support of the Victorian Government for the sector, providing significant funding for capabilities and supporting infrastructure.